Analysis of Cdc2 and cyclin D1 expression in breast cancer by immunoblotting

Breast Cancer

Volumn 4, Issue 1, 1997, Pages 17-24

  Ohta, Tomohiko ^a   Fukuda, Mamoru ^a   Arima, Kei ^a   Kawamoto, Hisanori ^a   Hashizume, Rintaro ^a   Arimura, Toshihiro ^a   Yamaguchi, Susumu ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Breast cancer; Cdc2; Cyclin D1; Prognosis

Indexed keywords

EID: 0242624205     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/BF02967050     Document Type: Article

References (29)

1. Kallioniemi OP, Kallioniemi A, Kurisu W, et al: erbB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proc Natl Acad Sci USA 89:5321-5325, 1992.
2. Borg A, Baldetorp B, Ferno M, et al: erbB2 amplification in breast cancer with a high rate of proliferation. Oncogene 6:137-143, 1991. (Pubitemid 21923993)
3. Coles C, Condie A, Chetty U, et al: p53 mutation in breast cancer. Cancer Res 52:5291-5298, 1992.
4. Runnebaum IB, Nagarajan M, Bowman M, et al: Mutation in p53 as potential molecular marker for human breast cancer. Proc Natl Acad Sci USA 88:10657-10661, 1991. (Pubitemid 21915896)
5. Isola J, Visakorpi T, Holli K, et al: Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in nodenegative breast cancer patients. J Natl Cancer Inst 84:1109-1114, 1992.
6. Hartmann LC, Ingle JN, Wold LE, et al: Prognostic value of c-erbB2 overexpression in axillary lymph node positive breast cancer; Results from a randomized adjuvant treatment protocol. Cancer 74:2956-2963, 1994. (Pubitemid 24361081)
7. Lowenstein EJ, Daly RJ, Batzer AG, et al: The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling. Cell 70:431-442, 1992.
8. Li Y, Jenkins CW, Nichols MA, et al: Cell cycle expression and p53 regulation of the cyclin-dependent kinase inhibitor p21. Oncogene 9:2261-2268, 1994. (Pubitemid 24228676)
9. Hunter T, Pines J: Cyclins and cancer; Cyclin D and CDK inhibitors come of age. Cell 79:573-582, 1994. (Pubitemid 24363801)
10. Loyer P, Glaise D, Cariou S, et al: Expression and activation of cdks (1 and 2) and cyclins in the cell cycle progression during liver regeneration. J Biol Chem 269:2491-2500, 1994. (Pubitemid 24235741)
11. Stein GH, Drullinger LF, Robetorye RS, et al: Senescent cells fail to express cdc2, cycA, and cycB in response to mitogen stimulation. Proc Natl Acad Sci USA 88:11012-11016, 1991. (Pubitemid 21915969)
12. Ewen ME, Sluss HK, Sherr CJ, et al: Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell 73:487-497, 1993. (Pubitemid 23143348)
13. Hinds PW, Dowdy SF, Eaton EN, et al: Function of a human cyclin gene as an oncogene. Proc Natl Acad Sci USA 91:709-713, 1994. (Pubitemid 24041471)
14. Gillet C, Fantl V, Smith R, et al: Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res 54:1812-1817, 1994. (Pubitemid 24116192)
15. cdc2 as a breast cancer prognostic factor. J Jpn Soc Cancer Ther 31:107-115, 1996.
16. Ohta T, Fukuda M, Wanebo HJ, et al: Behavior of the cell cycle-associated proteins in an unusual G0-arrestable cancer cell line. Exp Cell Res 225:85-92, 1996. (Pubitemid 26158458)
17. Gasparini G, Boracchi P, Verderio P, et al: Cell kinetics in human breast cancer; Comparison between the prognostic value of the cytofluorimetric S-phase fraction and that of the antibodies to Ki-67 and PCNA antigens detected by immunocytochemistry. Int J Cancer 57:822-829, 1994. (Pubitemid 24216818)
18. Witzig TE, Ingle JN, Cha SS, et al: DNA ploidy and the percentage of cells in S-phase as prognostic factors for women with lymph node-negative breast cancer. Cancer 74:1752-1761, 1994. (Pubitemid 24301830)
19. van Dierendonck JH, Wijsman JH, Keijzer R, et al: Cell-cycle-related staining patterns of anti-proliferating cell nuclear monoclonal antibodies; Comparison with BRdU labeling and Ki-67 staining. Am J Pathol 138:1165-1172, 1991.
20. Draetta G, Beach D: Activation of cdc2 protein kinase during mitosis in human cells; Cell cycle dependent phosphorylation and subunit rearrangement. Cell 54:17-26, 1988.
21. Dunphy WG, Briznela L, Beach D, et al: The Xenopus cdc2 protein is a component of MPF, a cytoplasmic regulator of mitosis. Cell 54:423-431, 1988.
22. Draetta G, Luca F, Westendorf J, et al: cdc2 protein kinase is complexed with both cyclin A and B; Evidence for proteolytic inactivation of MPF. Cell 56:829-838, 1989. (Pubitemid 19082518)
23. Koff A, Giordano A, Desai D, et al: Formation and activation of a cyclin E-cdk2 complex during the Gl phase of the human cell cycle. Science 257:1689-1694, 1992.
24. cdk2 is a component of the E2F-cyclin A complex. Cell 68:167-176, 1992.
25. Buckley MF, Sweeney KJ, Hamilton JA, et al: Expression and amplification of cyclin genes in human breast cancer. Oncogene 8:2127-2133, 1993. (Pubitemid 23226946)
26. Sherr CJ: Mammalian G1 cyclins. Cell 73:1059-1065, 1993.
27. Tsuchiya A, Nihei M, Ando Y, et al: The relationship of estrogen receptor status to DNA ploidy in breast cancer. Surg Today 22:105-109, 1992.
28. Komaki K, Mori T, Morimoto T, et al: Correlation between estrogen receptor status and histological malignancy in human breast cancer. J Surg Oncol 46:185-189, 1991.
29. Hynes RO, Lander AD: Contact and adhesive specificities in the associations, migrations, and targeting of cells and axons. Cell 68:303-322, 1992.